Table 2.

List of publications meeting the selection criteria for discussion of B7-H3-targeted RIT.

Type of study	Tumor type in study	RIC used	Major result	Refs.
Preclinical	Human rhabdomyosarcoma	¹³¹I-8H9, ¹²⁵I-8H9	Targeted RIT with ¹³¹I-8H9 significantly inhibited growth of s.c. human rhabdomyosarcoma xenografts in mice relative to controls (no treatment or isotype control RIC) with no adverse toxicological effects	[87]
Preclinical	N/A	¹³¹I-8H9, ¹²⁴I-8H9	CED of RICs in brainstem of healthy rats and non-human primates showed no adverse toxicology	[88]
Clinical phase I (18 patients)	Metastatic CNS neuroblastoma	¹³¹I-8H9, ¹²⁴I-8H9	Intrathecal RIT with ¹²⁴I-8H9 (up to 2220 MBq) in combination with alternative therapy was tolerable and resulted in durable complete responses	[12]
Clinical (retrospective, 96 patients)	Metastatic CNS neuroblastoma or medulloblastoma	¹³¹I-8H9	Intrathecal RIT after external radiation therapy resulted in low rate (1–2%) of radiation necrosis	[89]
Clinical (retrospective, 3 patients)	CNS relapsed rhabdomyosarcoma	¹³¹I-8H9	Intrathecal RIT after resection and external radiation therapy resulted in longer survival compared to no RIT	[90]
Clinical phase I (28 patients)	DIPG	¹²⁴I-8H9	No grade 4 adverse effects after CED of RIT (up to 148 MBq) with high retention of activity in the brainstem	[91–92]
Preclinical	Human ovarian cancer	²¹²Pb-376.96	RIT with ²¹²Pb-376.96 significantly prolonged survival of mice with i.p. tumor xenografts relative to controls (no treatment or isotype control RIC)	[25]
Preclinical	Human PDAC	²¹²Pb-376.96	Targeted RIT with ²¹²Pb-376.96 significantly inhibited growth of s.c. PDX PDAC tumors in mice relative to controls (no treatment or isotype control RIC)	[26]
Preclinical	Human RCC	¹³¹I-4H7	Targeted RIT with ¹³¹I-4H7 significantly inhibited growth of s.c. RCC xenografts in mice relative to controls (no treatment or isotype control RIC)	[93]